Eli Lillyvs.Insulet
LLY vs PODD · both in Diabetes & metabolic disease, part of the Medicine, pharma & life science value chain: Treatment and monitoring of diabetes and metabolic disease, from insulin to glucose monitoring.
Eli Lilly is about 118× larger than Insulet by market cap; Insulet trades at the lower P/E (24.8 vs 41.0); year to date, Eli Lilly leads (+10.6% vs −52.7%).
Side by side
| LLY | PODD | |
|---|---|---|
| Market cap | $1.1T | $9.3B |
| Price | $1,169.60 | $134.47 |
| Today | −1.6% | +0.1% |
| Return YTD | +10.6% | −52.7% |
| Return 1Y | +40.9% | −57.1% |
| Since June 26, 2026 | −3.2% | −15.0% |
| P/E | 41.0 | 24.8 |
| P/S | 13.8 | 3.1 |
| P/B | 32.3 | 6.2 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Eli LillyLLY
Mounjaro and Zepbound put Lilly at the centre of the GLP-1 market. Around them sit the diabetes and insulin business and franchises in oncology and neurology, with a pipeline that ranks among the strongest in the industry.
Full LLY profile →InsuletPODD
Maker of Omnipod, a tubeless insulin pump that handles dosing automatically.
Full PODD profile →More LLY & PODD comparisons
Other head-to-heads in the Diabetes & metabolic disease segment.